NovaMedica expands its line of products for the treatment of Alzheimer’s disease

Russian pharmaceutical company NovaMedica (RUSNANO portfolio company) has added Alzer^®-H (INN Donepezil) for the treatment of dementia associated with Alzheimer’s disease to its portfolio. Combination of the new product with NovaMedica’s other complementary drugs will allow Russian doctors to provide modern therapy at various stages of the disease and will increase availability of effective treatment for Russian patients.

Alzer^®-H (INN Donepezil) is prescribed for the treatment of mild to moderate Alzheimer’s dementia. It is also used for gradual increase of dosage strength (titration) when transferring patients to the next stage of therapy if their disease is progressing. To help patients at this stage, NovaMedica already has in its portfolio the combination drug Mioreol^® (INN Donepezil and Memantine) which has proven its effectiveness in the treatment of moderate to severe Alzheimer’s dementia. Therefore, Alzer^®-H is a logical addition to the company’s product line, and its successive combination with Mioreol^® will expand variability of treatment and will allow Russian doctors to implement modern effective therapy for a wide range of patients in accordance with the Federal Clinical Guidelines for the Diagnosis and Treatment of Alzheimer’s Disease

Elena Litvinova, CEO of NovaMedica LLC: “NovaMedica continues to implement the strategy of expanding its portfolio of products for the treatment of central nervous system (CNS) diseases in those segments where the need for medicines in Russia is not fully met, including for the treatment of Alzheimer’s disease. Responding to the demand of the medical community and patients, NovaMedica has strengthened its portfolio by adding the widely-demanded drug Alzer^®-H, thus solving several problems at once: providing access to this medicine for tens of thousands of Russian patients suffering from Alzheimer’s disease, localizing production to avoid the risk of shortages, and ensuring high availability of the drug in pharmacies at an affordable price. Alzer^®-H is highly rated by healthcare professionals, and its presence in Russia, along with the access to our line of other CNS products, will allow doctors to take a more comprehensive approach to planning the treatment of dementia.”

Alzer^®-H is manufactured in Russia in compliance with GMP rules and ISO standards at the site of MAKIZ-PHARMA LLC, part of HETERO Group of Companies (India). NovaMedica is responsible for marketing and promotion of the drug.

For information: Alzheimer’s disease is the most common cause of dementia – according to WHO, it accounts for 60-70% of all cases. There are about 55 million people with dementia in the world, and almost 10 million new cases are diagnosed annually*.

* Dementia. 03/15/2023. World Health Organization https://www.who.int/ru/news-room/fact-sheets/detail/dementia

_______________________________

NovaMedica LLC is a Russian pharmaceutical company specializing in development and manufacturing of innovative drugs that meet the special needs of patients with diseases of the central nervous system.

The company’s portfolio includes such products as Relonova^®, the first drug in Russia for migraine therapy based on the Rizatriptan molecule, Levroso^® Long, the only combination in the world of prolonged-release Melatonin and Diphenhydramine for the treatment of sleep disorders, Difendum^®, a unique medication in soft gelatin capsules based on Diclofenac potassium for the relief of various types of pain, Mioreol^®, the only fixed combination in Russia of Memantine and Donepezil for the treatment of Alzheimer’s dementia, and others.

NovaMedica Innotech Technology Center (subsidiary of NovaMedica) is located in the special economic zone Technopolis Moscow and includes a pharmaceutical development (R&D) center, as well as pilot and full-scale manufacturing sites.